tbuckley/cabot-search huggingface dataset:
MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
Authors: Paul G. Richardson, Amine Bensmaine, Thomas Doerr, Jianming Wang, Mohamed H. Zaki
Journal: Journal of Clinical Oncology (2015)

TPS8610 Background: Combination treatment (Tx) with immunomodulatory agents and proteasome inhibitors can provide deep and durable responses in patients (pts) with RRMM (Richardson, Blood, 2013). PVD showed promising activity and was well tolerated in a Ph 1 dose-escalation study (Richardson, ASCO, 2014). MM-007 is a global, multicenter, randomized, open-label Ph 3 trial designed to compare efficacy and safety of PVD vs VD in pts with RRMM (target enrollment: 782 pts; NCT01734928). Methods: Pts must have received 1-3 prior lines of anti-MM Tx, including ≥ 2 consecutive cycles (C) of a lenalidomide-containing regimen. Exclusion criteria include refractory to prior BORT 1.3 mg/m2 twice weekly, ANC < 1000/μL, platelet count < 75,000/µL ( < 30,000/μL for pts with ≥ 50% bone marrow plasma cells), CrCl < 30 mL/min requiring dialysis, hemoglobin < 8 g/dL, and peripheral neuropathy ≥ grade 2. Pts will be randomized 1:1 to continuous Tx with PVD or VD q3w until progression or unacceptable toxicity. PVD (arm A): POM 4 mg on D1-14; BORT SC 1.3 mg/m2 on D1, 4, 8, 11 for C1-8, D1, 8 for C9+; and D 20 mg (10 mg for pts > 75 y) on D1, 2, 4, 5, 8, 9, 11, 12 for C1-8, D1, 2, 8, 9 for C9+. VD (arm B): BORT and D same as arm A. Thromboprophylaxis with low-dose aspirin or equivalent is required for pts treated with PVD (VD if prior history of deep vein thrombosis or pulmonary embolism). The primary endpoint is progression-free survival (PFS). Secondary endpoints are overall survival (OS), safety, overall response rate by modified IMWG criteria, and duration of response. Exploratory endpoints include evaluation of PFS2, clinical benefit rate, PK, and HRQOL. Minimal residual disease, genomic, molecular/mechanistic, and immune biomarkers will be evaluated. Upon Tx discontinuation, follow-up will continue for subsequent anti-MM Tx, OS, and second primary malignancies. As of Jan 2015, 62 sites have opened in the US and 53 pts have been enrolled. Top enrolling US sites include Dana-Farber Cancer Inst, MA; UT SW Medical Ctr, TX; Gabrail Cancer Ctr, OH; and NW Georgia Oncology Ctr, GA. Sites are planned for Italy, Spain, France, and the rest of the world. Clinical trial information: NCT01734928.
COMPARISON OF OPTICAL COHERENCE TOMOGRAPHY VERSUS INTRAVASCULAR ULTRASOUND DETECTION OF TISSUE PROTRUSION AND ACUTE STENT-VESSEL WALL MALAPPOSITION IN 498 PATIENTS AFTER DRUG-ELUTING STENT IMPLANTATION
Authors: Yongqing Lin, Mitsuaki Matsumura, Gary Mintz, Xiao Wang, Cheolmin Lee, Tsunekazu Kakuta, Akiko Maehara
Journal: Journal of the American College of Cardiology (2017)
ADMISSION TYPES AMONG PATIENTS WITH HEART FAILURE CARED FOR BY ACCOUNTABLE CARE ORGANIZATIONS: VARIATION BY PERFORMANCE ON A MEASURE OF RISK STANDARDIZED ACUTE ADMISSION RATES
Authors: Liliya Benchetrit, Chloe O. Zimmerman, Haikun Bao, Kumar Dharmarajan, Faseeha Atlaf, Jeph Herrin, Zhenqiu Lin, Harlan Krumholz, Elizabeth Drye, Kasia Lipska, Erica Spatz
Journal: Journal of the American College of Cardiology (2017)
TIMING AND ALGORITHM OF PERMANENT PACEMAKER IMPLANTATION AFTER TAVR
Authors: Ijeoma Ananaba Ekeruo, Michael Firstenberg, Roxana Mehran, David Fullerton, Vinod Thourani, Kyle Mitchell, Gina De La Guardia, Prakash Balan, Alistair Philips, Jodie Hurwitz, Tom Nguyen
Journal: Journal of the American College of Cardiology (2017)
UNIQUE CHARACTERISTICS OF THE MITRAL VALVE IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY HAVE EMERGED USING REAL-TIME THREE DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAPHY
Authors: Erifili Venieri, Constantina Aggeli, Aris Anastasakis, Elisavet Sfendouraki, Christodoulos Stefanadis, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
Challenges to accrual predictions to phase III cancer clinical trials: A survey of study chairs and lead statisticians of 248 NCI-sponsored trials
Authors: A. T. Schroen, G. R. Petroni, H. Wang, B. Djulbegovic, C. L. Slingluff, X. F. Wang, R. Gray, D. J. Sargent, W. Cronin, J. Benedetti
Journal: Journal of Clinical Oncology (2009)

6562 Background: Trial closure due to inadequate accrual presents a common problem in cancer research. We sought to identify factors related to trial design common to trials with successful versus unsuccessful accrual. Methods: In 2008, a 30-question web-based survey was sent to the study chair (SC) and lead statistician (LS) for all 248 phase III trials open in 1993–2002 by five national cooperative groups (NCG). SC and LS level of experience, trial design elements, accrual predictions, and perceived accrual influences were queried. Accrual success was categorized based on NCG records: successful trials (ST) closed with complete accrual or at interim analysis while unsuccessful trials (UT) closed due to inadequate accrual. Responses were analyzed by respondent role (SC/LS) and accrual success. Results: 309 eligible responses were included (response rate, 62%: LS 81%, SC 45%). Respondents represented ST (65%) and UT (35%) with no response bias by accrual success. SC academic rank was not linked to accrual success. Literature review, SC experience, and expert opinion within NCG most commonly influenced control arm selection, but did not impact accrual success. NCG experience had the greatest influence on accrual predictions in both ST and UT. Trials comparing novel with established therapies were more likely to be ST (72%) than UT (28%); head-to-head comparisons of established therapies were more equally divided between ST (59%) and UT (41%). Among the 41% of respondents citing significant accrual difficulties, no factors negatively influencing accrual were consistently identified. Among respondents not citing accrual difficulties, factors credited with positively influencing accrual were clinical relevance of study question, lack of competing trials, and protocol paralleling normal practice. Conclusions: No consistent factors were identified to explain poor trial accrual, suggesting that reasons for poor accrual are not well understood and warrant further study. An objective measure of clinical relevance would be useful to inform trial prioritization practices. Research into alternative strategies for accrual prediction is needed since NCG experience is linked to both successful and unsuccessful accrual. [Table: see text]
USING MACHINE LEARNING TO DEFINE THE ASSOCIATION BETWEEN CARDIORESPIRATORY FITNESS AND ALL-CAUSE MORTALITY: THE FIT (HENRY FORD EXERCISE TESTING) PROJECT
Authors: Mouaz H. Al-Mallah, Amjad Ahmed, Waqas Qureshi, Radwa Elshawi, Clinton Brawner, Michael Blaha, Haitham Ahmed, Jonathan Ehrman, Steven Keteyian, Sherif Sakr
Journal: Journal of the American College of Cardiology (2017)
A HUMAN FETAL UP-REGULATED LNCRNA TRIGGERS ENDOGENOUS HEART REGENERATION BY DEPHOSPHORYLATION OF MITOTIC CENTROMERE-ASSOCIATED KINESIN
Authors: Yanmei Chen, Xinzhong Li, Guojun Chen, Lintao Zhong, Xiang He, Chixiong Huang, Bing Li, Hairui Li, Shifei Wang, Yuanwen Jing, Jianping Bin
Journal: Journal of the American College of Cardiology (2017)
Changing causes of death post-epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) era in patients with advanced non-small cell lung cancer (NSCLC).
Authors: Wen Shuo Wu, Yuh-Min Chen, Chun-Ming Tsai, Jen-Fu Shih, Yu-Chin Lee, Reury-Perng Perng
Journal: Journal of Clinical Oncology (2012)

e18132 Background: EGFR-TKIs are effective against tumor EGFR-mutated NSCLC. Patients with tumor EGFR activating mutation (EGFRmu) (exon 19 deletions or exon 21 L958R) had better survival than those with EGFR wild-type tumors (EGFRwt). Many EGFRmu patients have had disease progression with EGFR-TKI treatment due to central nervous system (CNS) metastases, including meningeal carcinomatosis. The objective of this retrospective study is to compare the causes of death in patients with a known tumor EGFR mutation status who had been treated with EGFR-TKIs. Methods: We retrospectively reviewed the chart records of our advanced NSCLC patients who had received diagnosis, treatment, and supportive and hospice care in our hospital between July 2005 and June 2010. Tumor EGFR mutation status was analyzed using the DNA sequence method. All enrolled patients had a documented cause of death. Results: Ninety-four patients had documented tumor EGFR data, had received EGFR-TKI treatment (either erlotinib or gefitinib), and were with or without previous or salvage systemic chemotherapy. Of them, 36 were EGFRwt and 58 were EGFRmu. Overall survival after starting EGFR-TKI treatment was significantly longer in EGFRmu than in EGFRwt patients (median 68.9 weeks vs. 46.3 weeks, p=0.0058). Twenty-nine patients died of CNS metastases and 65 died of organ(s) failure other than the CNS. Patients who died of CNS metastases had undergone EKGF-TKI treatment significantly longer than those who died of other organ(s) failure (median 32 weeks vs. 7.7 weeks, p=0.0003), with a hazard ratio of 2.308 (95% C.I. 1.452-3.668, p=0.0004). A significantly higher proportion of EGFRmu patients died of CNS metastases (26 of 58, 44.8%) than EGFRwt patients (3 of 36, 8.3%) (p&lt;0.001). Conclusions: EGFRmu NSCLC patients survived longer and had a significantly higher probability of mortality due to CNS metastases than EGFRwt patients. This change in the causes of death due to NSCLC was noted after an era of EGFR-TKI treatment, and will have an important impact on the strategies or management of patient supportive and hospice care.
Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (Mabthera®) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma
Authors: Auro Viswabandya, Asis Mukhopadhyay, Sandip Shah, Rajnish Vasant Nagarkar, Sonica Sachdeva Batra, Luis Lopez Lazaro, Suresh Kankanwadi, Alok Srivastava
Journal: Blood (2016)
Erratum: Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia
Authors: Johan Rung, Stéphane Cauchi, Anders Albrechtsen, Lishuang Shen, Ghislain Rocheleau, Christine Cavalcanti-Proença, François Bacot, Beverley Balkau, Alexandre Belisle, Knut Borch-Johnsen, Guillaume Charpentier, Christian Dina, Emmanuelle Durand, Paul Elliott, Samy Hadjadj, Marjo-Riitta Järvelin, Jaana Laitinen, Torsten Lauritzen, Michel Marre, Alexander Mazur, David Meyre, Alexandre Montpetit, Charlotta Pisinger, Barry Posner, Pernille Poulsen, Anneli Pouta, Marc Prentki, Rasmus Ribel-Madsen, Aimo Ruokonen, Anelli Sandbaek, David Serre, Jean Tichet, Martine Vaxillaire, Jørgen F P Wojtaszewski, Allan Vaag, Torben Hansen, Constantin Polychronakos, Oluf Pedersen, Philippe Froguel, Robert Sladek
Journal: Nature Genetics (2009)
THE ROLE OF GENDER ON MESENCHYMAL STEM CELL THERAPY IN NON-ISCHEMIC DILATED CARDIOMYOPATHY: A SUB-ANALYSIS OF THE POSEIDON-DCM TRIAL
Authors: Victoria Florea, Ana M. Landin, Angela M. Castellanos, Makoto Natsumeda, Bryon A. Tompkins, Courtney Premer, Darcy Difede, Wayne Balkan, Ivonne H. Schulman, Joshua Hare
Journal: Journal of the American College of Cardiology (2017)
Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Authors: Maria Catherine Pietanza, Alexander I. Spira, Robert M. Jotte, Shirish M. Gadgeel, Alain C. Mita, Lowell L. Hart, W Larry Gluck, Anne C. Chiang, Stephen V. Liu, Ann M. Kapoun, Lu Xu, Dawn Hill, Jakob Dupont, David R. Spigel, Lei Zhou
Journal: Journal of Clinical Oncology (2015)

7508 Background: Notch signaling is implicated in cancer stem cell self-renewal and proliferation; thus being an appealing target in the treatment of SCLC. Tarextumab (TRXT), a fully human IgG2 antibody targeting Notch2 and 3 receptors, has shown preclinical efficacy in SCLC models with cisplatin. This Phase Ib study explores the MTD, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of TRXT with EP in chemo-naive ED-SCLC. Methods: Notch signaling is implicated in cancer stem cell self-renewal and proliferation; thus being an appealing target in the treatment of SCLC. Tarextumab (TRXT), a fully human IgG2 antibody targeting Notch2 and 3 receptors, has shown preclinical efficacy in SCLC models with cisplatin. This Phase Ib study explores the MTD, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of TRXT with EP in chemo-naive ED-SCLC. Results: By November 18, 2014, 27 pts were treated with TRXT at dose range from 5 mg/kg to 15 mg/kg. The MTD was not reached and TRXT 15 mg/kg was determined to be the Phase 2 dose. One DLT of Grade 3 nausea and vomiting was reported in the 10 mg/kg dose cohort. Frequently reported ( ≥ 15%) TRXT-related adverse events were: diarrhea (59.3%), fatigue (44.4%), nausea (40.7%), anemia (25.9%), decreased appetite (25.9%) and vomiting (25.9%); most were Grade 1 or 2 and managed with supportive care. The overall response rate was 84%. The median duration of treatment was 128 days (6 cycles) with mPFS and mOS of 124 and 228 days, respectively. The median follow-up for PFS and OS was of 86 and 107 days respectively. Conclusions: TRXT with EP is well tolerated. Encouraging anti-tumor activity has been observed. Final safety, efficacy, PK, immunogenicity and predictive biomarker results will be presented. TRXT at a dose of 15 mg/kg has been selected for the phase 2 randomized, placebo-controlled portion of the study, which is ongoing. Clinical trial information: NCT01859741.
COMPLICATION RATES OF EPICARDIAL VENTRICULAR TACHYCARDIA ABLATION: A POOLED ANALYSIS
Authors: Naga Venkata K. Pothineni, Anusha Shanbhag, Ajoe Kattoor, Swathi Kovelamudi, Ammar Killu, Siva Mulpuru, Suraj Kapa, Abhishek Deshmukh
Journal: Journal of the American College of Cardiology (2017)
Paclitaxel (PTX) as second line treatment in patients (pts) with small cell lung cancer (SCLC) refractory to carboplatin - etoposide: A multicenter phase II study
Authors: G. Joos, D. Schallier, P. Pinson, M. Sterckx, J. P. Van Meerbeeck
Journal: Journal of Clinical Oncology (2004)

7211 Background: pts non-responding to 1st line chemotherapy or relapsing within 3 months (m) of confirmed prior response are considered refractory to treatment and candidate for phase II trials, as second line therapy in refractory SCLC is disappointing (Huisman, 1999). The present study aimed to assess the activity and toxicity of single agent PTX in pts refractory to first line carboplatin and etoposide. Methods: Eligible pts had to present with cytological or histological proof of SCLC, at least 1 measurable lesion, WHO PS ≤ 2, age ≥ 18 years, and adequate renal, hepatic and bone marrow function. After informed consent, pts were treated in first line with carboplatin AUC 6 on d1 or 100 mg/m2 on d1–3 and etoposide 120 mg/m2 on d1–3, q 4w for up to 6 cycles Refractory pts were treated with PTX 200 mg/m2 as a 3 h infusion q 3w for up to 6 cycles, after adequate premedication. Appropriate dose reductions were made according to toxicity. The prophylactic use of CSF's was not allowed. PCI was optional and thoracic irradiation mandatory in LD pts obtaining response. Response and toxicity were defined using WHO and NCI-CTC criteria, respectively. The study was powered to detect a true response rate of PTX ≥ 20% using a 2 step design according to Gehan with a 2-sided alpha error of 0.05 and a beta error of 0.1. Results: between October 1998 and August 2001, 93 pts with the following characteristics started 1st line therapy: male 98%, median age 66 years (range 39–88), WHO PS 0/1/2: 18/75/7%, Extensive stage 55%. 44 refractory pts, of whom 52% non-responders to 1st line, received PTX. Mean number of PTX cycles was 3 (range 1–6). The ORR was 20% (95%CI 11–29%). Toxicity was evaluable in 40 pts:grade ¾ (%): fatigue 13/-, dyspnea 5/-, neuropathy 8/-, arthralgia/myalgia 8/-, anemia 5/-, febrile neutropenia: 23% . No toxic deaths were observed, although 3 pts died of disease progression during treatment. Median OS and TTP on PTX were 4 and 3 m, respectively. Conclusions: the observed activity of PTX in pts with refractory SCLC looks promising, provided febrile neutropenia can be avoided/prevented. No significant financial relationships to disclose.
A pilot phase II study of consolidation chemotherapy with docetaxel and cisplatin following concurrent chemoradiotherapy (CCRT) for locoregionally advanced head and neck squamous cell carcinoma (HNSCC)
Authors: Y. Lee, S. Lee, K. Lee, S. Park, E. Cho, D. Shin
Journal: Journal of Clinical Oncology (2006)

5549 Background: With the improvement seen with CCRT in the management of locoregionally advanced HNSCC, distant failures have become a more relevant problem in terms of survival. As a consequence, more effective strategies including consolidation chemotherapy are warranted. The primary objective of this pilot phase II study was to assess the feasibility and efficacy of docetaxel and cisplatin consolidation following primary CCRT for HNSCC. Methods: Thirty-three patients with previously untreated, stage III/IV HNSCC participated in this study. CCRT consisted of cisplatin 100 mg/m 2 on day 1, 22 and 43. Concurrent radiotherapy (70 Gy) to the primary tumor and neck was performed over a period of 7 weeks. After completion of CCRT, patients with no evidence of disease progression received an additional 4 cycles of consolidation chemotherapy with docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 every 3 weeks. To minimize the expected accrual into unacceptable treatment, either in terms of clinical response or toxicity, a total of 35 patients would be required in a two-stage design. Results: Baseline characteristics were: male (22), median age (60 years), ECOG performance status 0/1 (15/18), stage III/IV (10/23). Of these, 27 (81%) patients completed CCRT. After CCRT, 3 complete and 19 partial responses were recorded, giving an overall response rate of 67% (95% CI, 51–83%). Of the 19 patients who went to consolidation phase, only 4 (21%) completed all 4 cycles of docetaxel and cisplatin. Failure to consolidation chemotherapy was attributed to the following causes: toxicity (11 including 3 treatment-related deaths), disease progression (4). During consolidation chemotherapy, 13 patients (68%) had grade 3/4 neutropenia and febrile neutropenia occurred in 6 (32%). With consolidation chemotherapy, one patient with initial stable disease achieved a partial response. Median survival in all patients was 11.0 months, and 8.3 months for those treated with consolidation chemotherapy. Conclusions: The poor compliance and the high incidence of severe toxicities, including 3 treatment-related deaths, prompted no further evaluation of this consolidation chemotherapy following CCRT. No significant financial relationships to disclose.
Interferon-γ Perturbs Key Signaling Pathways Induced By Thrombopoietin, but Not Eltrombopag, in Human Hematopoietic Stem/Progenitor Cells
Authors: Hai Cheng, Patali S. Cheruku, Luigi Alvarado, Ayla Cash, Cynthia E. Dunbar, Neal S. Young, Andre Larochelle
Journal: Blood (2016)
INDEX OF MICROCIRCULATORY RESISTANCE FOR PREDICTING SEVERITY OF MYOCARDIAL INJURY AND CARDIAC FUNCTION AFTER ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A CARDIAC MAGNETIC RESONANCE IMAGING STUDY
Authors: Takayuki Onishi, Yuko Onishi, Isshi Kobayashi, Shigeo Umezawa, Akihiro Niwa
Journal: Journal of the American College of Cardiology (2017)
Detection of human papillomavirus DNA from the breast carcinomas and the cervix: Are they correlated?
Authors: J. Choi, H. Lim, W. Kim, S. Lee, S. Kim, S. Kim, D. Kim, E. Cho, J. Lee, S. Nam, J. Yang
Journal: Journal of Clinical Oncology (2009)

1544 Background: The association between human papillomavirus (HPV) and cervical cancer is well known. However, it remains unclear whether there is also a correlation between HPV infection and human breast cancer. The aim of this study is to investigate the hypothetic association between HPV infection and breast carcinoma through the comparison of the type of HPV infection in the breast and cervix. Methods: From April to December 2008, 106 patients who were diagnosed as breast cancer and underwent mastectomy were analyzed. Their breast tissue (tumor, normal parenchyme, and nipple-areolar complex) and cervix smear were analyzed for HPV infection with DNA chip microarray method. Results: 24 patients (23.1%) showed HPV infection in their cervix smear; high-risk type of HPV was found in 12 patients. But only six patients (5.8%) revealed the HPV infection in breast cancer; half of them were high-risk group (HPV-16, 31); the same types of HPV was found at the normal breast tissue in two patients of them. However, there were no patients with HPV infection in both breast and cervix concurrently. Conclusions: There were no positive results for HPV infection of cervix in HPV-infected breast cancer patients. Also, we cannot find that the presence of high-risk HPV in the breast might be related to the breast carcinogenesis. We concluded that HPV infection is not correlated to the carcinogenesis of breast. No significant financial relationships to disclose.
Sequential metastatic biopsies and functional imaging in breast cancer.
Authors: Theodoros Foukakis, John Lovrot, Patricia Sandqvist, Hanjing Xie, Linda Sofie Lindström, Carla Giorgetti, Hans Jacobsson, Elham Hedayati, Jonas C. S. Bergh
Journal: Journal of Clinical Oncology (2014)

e22120 Background: Classical histopathological markers usually determined in the primary tumor are used for therapy selection and prognostication in metastatic breast cancer. Data on the prognostic or predictive value of gene expression profiling of metastases are limited. Methods: Patients enrolled in a phase III trial of metastatic breast cancer with docetaxel monotherapy versus combination of docetaxel + sunitinib were offered to participate in a translational substudy comprising sequential fine needle aspiration biopsies and Positron Emission Tomography imaging, before (time point T1) and two weeks after start of treatment (time point T2). Aspirated tumor material was used for gene expression profiling, and treatment-induced changes (T2 versus T1) in gene expression and standardized uptake values (SUV) were investigated. Results: Gene expression profiling yielded high-quality data at both time points in 14 of 18 (78%) patients. Unsupervised 2-means clustering revealed specific patterns of changes caused by monotherapy vs. combination therapy (p = 0.021, by Fisher’s exact test). A therapy-induced reduction of known proliferation and hypoxia metagenes was seen across the dataset, with more prominent changes in the combination arm. The change in mean SUV was strongly correlated to changes of target lesions assessed by Computed Tomography scan at 6 weeks versus baseline in monotherapy, Spearman’s rho=0.833 (p=0.008), but not in the combination arm rho=-0.029 (p=1). Contrary, the reductions seen in the hypoxia metagene score were a predictor of response in the combination arm, rho=1 (p=0.017) but not in monotherapy, rho=-0.029 (p=1). A strong correlation was also seen between tumor size changes at 12 weeks and the PAM50 proliferation index in the combination arm (rho=1, p=0.017). Conclusions: Gene expression profiling of sequential metastatic aspiration biopsies was feasible, demonstrated biological validity and provided predictive information in a randomized trial of metastatic breast cancer.
C-REACTIVE PROTEIN IN NON-ST ELEVATION MYOCARDIAL INFARCTION PATIENTS IS USEFUL IN IMPROVING DISCRIMINATION OF CONVENTIONAL RISK SCORE: A REPORT FROM MULTICENTER PCI REGISTRY
Authors: Toshiomi Katsuki, Mitsuaki Sawano, Ikuko Ueda, Nobuhiro Ikemura, Kenichiro Shimoji, Shigetaka Noma, Masahiro Suzuki, Yohei Numasawa, Kentaro Hayashida, Shinsuke Yuasa, Yuichiro Maekawa, Shun Kohsaka, Keiichi Fukuda
Journal: Journal of the American College of Cardiology (2017)